Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Autosomal Dominant Disorder

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: Autosomal Dominant Disorder. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2012-000550-60 Sponsor Protocol Number: V7/22032018 Start Date*: 2014-01-17
    Sponsor Name:Medizinische Universität Wien, Klinische Abteilung für Nephrologie und Dialyse, Universitätsklinik für Innere Medizin 3
    Full Title: Pulsed oral sirolimus in autosomal dominant polycystic kidney disease
    Medical condition: Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development and uncontrolled proliferation of innumerable epithelial-lined cysts that stem from renal...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002551-11 Sponsor Protocol Number: HP-CKDPKD Start Date*: 2022-01-18
    Sponsor Name:Aarhus University
    Full Title: Chronic kidney disease – imaging the metabolic derangements with ultra-sensitive MRI
    Medical condition: Chronic kidney disease and polycystic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.0 10010331 - Congenital, familial and genetic disorders 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002768-24 Sponsor Protocol Number: 156-04-251 Start Date*: 2007-01-26
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablet Regimens in Adult Subjects with Autosomal Dominant ...
    Medical condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed) BE (Completed) GB (Completed) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003062-12 Sponsor Protocol Number: PA-ADPKD-301 Start Date*: 2022-01-20
    Sponsor Name:Palladio Biosciences, Inc.
    Full Title: A Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants with Autosomal Dominant Polycystic Kidney Disease Consisting of a 1-year Double-blind, Placebo-controlled, Randomized Phase ...
    Medical condition: Autosomal Dominant Polycystic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) SK (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000187-42 Sponsor Protocol Number: 156-12-298 Start Date*: 2016-10-24
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3b, Two-part, Multicenter, One Year Randomized, Double-blind, Placebo-controlled Trial of the Safety, Pharmacokinetics, Tolerability, and Efficacy of Tolvaptan followed by a Two Year Open-l...
    Medical condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10036046 Polycystic kidney, autosomal dominant LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005949-16 Sponsor Protocol Number: 202000894 Start Date*: 2021-10-25
    Sponsor Name:University Medical Center Groningen
    Full Title: A GnRH Agonist IN pre-menopausal women STudy to treat severe Polycystic Liver Disease
    Medical condition: Severe polycystic liver disease in female patients
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10048834 Polycystic liver disease PT
    20.0 10010331 - Congenital, familial and genetic disorders 10036045 Polycystic kidney LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10036046 Polycystic kidney, autosomal dominant LLT
    23.0 10010331 - Congenital, familial and genetic disorders 10083939 Autosomal dominant polycystic liver disease LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017849-57 Sponsor Protocol Number: PCLD004 Start Date*: 2011-03-24
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Somatostatin analogues as a volume reducing treatment of polycystic livers
    Medical condition: Polycystic liver disease, due to isolated polycystic liver disease or polycystic kidney disease.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10048834 Polycystic liver disease LLT
    12.1 10048834 Polycystic liver disease PT
    12.1 10036045 Polycystic kidney LLT
    12.1 10036046 Polycystic kidney, autosomal dominant LLT
    12.1 10036048 Polycystic kidney, unspecified type LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004370-55 Sponsor Protocol Number: 2007-004370-55 Start Date*: 2007-12-14
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE)
    Full Title: Effects of tetrahydrobiopterin (6R-BH4) on flow-mediated dilation in CADASIL patients: a randomised controlled trial
    Medical condition: CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), is a rare autosomal dominant disorder characterized by recurrent strokes starting in mid-adulth...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008804 Chromosomal abnormalities and abnormal gene carriers HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001493-28 Sponsor Protocol Number: OPA1 Start Date*: 2020-09-24
    Sponsor Name:Medizinische Universität Graz, Univ.-Augenklinik
    Full Title: Raxone® treatment for patients with dominant optic atrophy due to OPA1 gene mutation
    Medical condition: Autosomal dominant optic atrophy (ADOA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10019895 Hereditary optic atrophy PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003427-37 Sponsor Protocol Number: SIRENA Start Date*: 2007-02-05
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: Sirolimus treatment in patients with autosomal dominant polycystic kidney disease renal efficacy and safety
    Medical condition: Autosomal-Dominant Polycystic Kidney Disease ADPKD
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010428 Congenital cystic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005047-21 Sponsor Protocol Number: SIRENA II Start Date*: 2007-12-24
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: Effects of Sirolimus on disease progression in patients with Autosomal Dominant Polycystic Kidney Disease and severe renal insufficiency
    Medical condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010428 Congenital cystic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004281-19 Sponsor Protocol Number: 1.5 Start Date*: 2022-06-08
    Sponsor Name:Region Stockholm Karolinska University Hospital (Dep. of Dermatology)
    Full Title: Investigator initiated clinical trial of dantrolene as a treatment for Darier disease
    Medical condition: Darier disease is a rare and severe autosomal dominant skin disorder.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005552-41 Sponsor Protocol Number: ALADIN Start Date*: 2006-02-20
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: Effect of long-acting somatostatin on disease progression in nephropathy due to autosomal dominant polycystic disease a long-term three year follow-up study
    Medical condition: Autosomal Dominant Polycystic Kidney Disease ADPKD
    Disease: Version SOC Term Classification Code Term Level
    6.1 10038359 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004400-34 Sponsor Protocol Number: LTS15823 Start Date*: 2021-03-23
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: Multicenter, open-label, extension study to characterize the long-term efficacy and safety of early versus delayed treatment with venglustat (GZ/SAR402671) in patients at risk of rapidly progressiv...
    Medical condition: Congenital cystic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010428 Congenital cystic kidney disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) NL (Completed) BE (Prematurely Ended) DE (Completed) PT (Prematurely Ended) IT (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-001485-16 Sponsor Protocol Number: CRAD001ADE12 Start Date*: 2006-12-15
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal domin...
    Medical condition: polycystic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011771 Cystic kidney disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-006557-25 Sponsor Protocol Number: RAPYD-STUDY Start Date*: 2007-12-20
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
    Full Title: RAPAMYCIN FOR TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
    Medical condition: ADPKD type I
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038359 Renal and urinary disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003585-40 Sponsor Protocol Number: NL.TACRO.10.7.19 Start Date*: 2019-12-17
    Sponsor Name:St. Antonius Hospital
    Full Title: An uncontrolled, open label pilot-study assessing the efficacy in reducing bleeding severity, and the safety of oral tacrolimus in patients with hereditary hemorrhagic telangiectasia
    Medical condition: Gastrointestinal bleeding and epistaxis caused by hereditary hemorrhagic telangiectasia. Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant inherited disease characterized by muco...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10038554 Rendu-Osler-Weber syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003784-94 Sponsor Protocol Number: MexLam Start Date*: 2022-01-20
    Sponsor Name:Rigshospitalet, department of Neurology
    Full Title: Treatment of Myotonia - Lamotrigine versus Namuscla
    Medical condition: Myotonia Congenita (Becker and Thomsen type), Paramyotonia Congenita, and Hyperkalemic periodic paralysis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10049841 Myotonia congenital LLT
    20.1 100000004850 10076440 Hyperkalemic periodic paralysis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001406-42 Sponsor Protocol Number: 30032016 Start Date*: 2016-12-20
    Sponsor Name:Hæmatologisk Afdeling, Sjælland Sygehus, Roskilde
    Full Title: Statin- and bisphosphonate treatment in patients with the Philadelphia-negative chronic myeloproliferative neoplasms - essential thrombocytosis, polycythemia vera and hypercellular myelofibrosis.
    Medical condition: The Philadelphia-negative chronic myeloproliferative neoplasms: Essential thrombocytosis, polycythemia vera and hypercellular myelofibrosis.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10028577 Myeloproliferative disorder NOS LLT
    19.0 100000004864 10074689 Post polycythemia vera myelofibrosis LLT
    19.0 100000004864 10028576 Myeloproliferative disorder LLT
    19.0 100000004864 10074692 Post essential thrombocythaemia myelofibrosis LLT
    19.0 100000004864 10074690 Post essential thrombocythemia myelofibrosis LLT
    19.0 100000004864 10074691 Post polycythaemia vera myelofibrosis LLT
    19.0 100000004864 10028538 Myelofibrosis with myelometaplasia LLT
    19.0 100000004864 10015495 Essential thrombocytosis LLT
    19.0 100000004864 10015494 Essential thrombocythemia LLT
    19.0 100000004864 10013238 Disorder myeloproliferative LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001162-40 Sponsor Protocol Number: E2020-A001-233 Start Date*: 2005-03-08
    Sponsor Name:Eisai Ltd
    Full Title: An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cog...
    Medical condition: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). CADASIL is a genetic disorder representing a minority of the patients who develop vascular de...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10057678 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) SE (Completed) GB (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:03:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA